Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JKB 122

Drug Profile

JKB 122

Alternative Names: JKB-122

Latest Information Update: 29 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jenken Biosciences
  • Developer Jenken Biosciences; TaiwanJ Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Small molecules
  • Mechanism of Action Immunomodulators; Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Autoimmune hepatitis; Crohn's disease; Hepatitis; Hepatitis C; Non-alcoholic fatty liver disease
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 02 Mar 2019 JKB 122 licensed to Newsoara Biopharma in Asia except Taiwan for the treatment of Non-alcoholic fatty liver disease
  • 21 Jan 2019 TaiwanJ Pharmaceuticals completes a phase II trial in Autoimmune hepatitis in USA (PO) (NCT02556372)
  • 21 Jan 2019 TaiwanJ Pharmaceuticals plans to file the phase II/III clinical study application for Autoimmune hepatitis to FDA in Q2, 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top